Microfluidics released earnings on Tuesday with good results:
- $ http://broughtonpublishing.com.au/order-disulfiram-uk-disulfiram-shipped-from-canada-category-disulfiram/ 4.5M in Q2 Revenue a 30% increase over the same quarter in 2009.
- Net Income of $143k compared to a loss of $177k in the same quarter of 2009.($396k before EBITA).
- Achieved a gross margin of 64%.
- Began shipping the LV1 low volume Microfluidizer.
- R&D,Selling and G&A increased by $552k over June 30,2009.
- Weighted Ave diluted shares outstanding are about 10.613,000.
- Stockholder equity has improved to $1,654,000 from $1.290.000.
Cash is $1,945,000 and the strattera no prescription Convertible Debt held by Abraxis click here for info (ABII) is $4,707,000. Abraxis has been sold to Celgene (CELG) for $2.9B which is expected to close by Q4 2010. It is not known whether Abraxis will retain its non-core investments in biotechnology such as any Microfluidics license or whether they go to Celgene. Abraxis is currently investing about $35.9M in R&D in the June quarter of 2010.
Assuming an $18M running rate for revenues and the current market cap of $8.85M the P/S of Microfluidics is 0.49.
Without having details of the Abraxis debt deal but modelling the conversion of all debt to equity at $1.20 would result in about 14,550 shares at $1.20 giving a market cap of $17.5M. Price to Sales would then be about 1.
The Microfluidics stock is not being traded in any volume as there are few sellers under $1.00 due to large insider holdings. Liquidity is lacking in the stock so it is more like investing in a private Company.MFLU is a value investment thesis based upon current valuations and the potential of expanding the market for creating nano-particles in the pharmaceutical and cosmetic industries and top line sales growth.
Disclosure :Raygent has a small position in the stock.